A genome-wide association study in 835 patients with psoriatic arthritis (PsA) and 1,558 healthy individuals has revealed a new PsA-specific risk locus in B3GNT2 and has highlighted the glycosaminoglycan (GAG) metabolism pathway as important in PsA. The results were validated in an independent cohort (n = 2,847) and the gene variants did not associate with psoriasis or rheumatoid arthritis when tested in 614 and 1,191 patients, respectively. Drug re-purposing analysis identified at least two FDA-approved drugs that target proteins encoded by genes in the GAG pathway as candidates for use in PsA.
References
Original article
Aterido, A. et al. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis. Ann. Rheum. Dis. https://doi.org/10.1136/annrheumdis-2018-214158 (2018)
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Collison, J. GAG metabolism associated with PsA risk. Nat Rev Rheumatol 15, 64 (2019). https://doi.org/10.1038/s41584-019-0161-6
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41584-019-0161-6
